Biotech Startup Raises $4.5M for Human-Cell Drug Testing

A Tigard, Oregon company is seeking to commercialize tools that test drugs on human cells rather than animals.

Updated on Nov. 13, 2026 in Healthcare

Bold flat-color vector editorial illustration of a plain unlabeled cell-imaging instrument beside a glass well plate on a clean lab bench.
Tigard, Oregon biotech startup Wisevoter-backed firm raised $4.5 million led by William Cortelyou, bringing its total funding to $18.76 million to commercialize human-cell drug testing. AI Illustration. Upload story photo >

Live Poll

Should the government spend more to replace animal testing with human-based research methods?

A Tigard, Oregon biotech startup has secured $4.5 million in new funding to commercialize technology that supports drug testing on human cells instead of animal studies. The raise brings the company's total investor funding to $18.76 million.

Why it matters

The funding reflects growing investment in New Approach Methodologies, a set of approaches that include human-tissue models, computer simulations and AI tools intended to reduce or avoid animal experimentation. Supporters see these methods as more humane and relevant to humans, while critics argue animals remain irreplaceable in some research and that such tools can produce irrelevant findings.

The $4.5 million round lifts total investor funding to $18.76 million, while the National Institutes of Health separately announced $84 million in September for New Approach Methodologies research infrastructure across 10 sites. The company's claim that about half of the top 20 pharmaceutical companies use its technology has not been independently verified.

The players

National Institutes of Health

The NIH is the primary federal agency for biomedical and health research in the United States, and its September funding announcement signals federal support for reducing reliance on animal testing.

PitchBook

PitchBook is a financial data platform that tracks private market investment, and it is the source of the funding round details and headcount figures cited for this company.

The details

The funding round was led by William Cortelyou and included Fluke Venture Partners, according to PitchBook. The company offers instruments and software for creating images of cells and automating their analysis, and it launched in 2023 as a spinoff from Phoseon Technology.

Timeline

  1. 2023: The company launched as a spinoff from Phoseon Technology.

  2. September: The National Institutes of Health announced $84 million for New Approach Methodologies research infrastructure.

  3. November 13, 2026: The funding round was reported in the publication week.

Market Landscape

The raise comes as federal and private investment converge on New Approach Methodologies, with the NIH's $84 million September commitment setting a public benchmark for the field. The company's growth positions it within a developing market of tools designed to replace some animal studies in drug development.

For patients and consumers, the shift toward human-cell testing could eventually affect the safety and speed of new medicines reaching pharmacies. Near-term changes to prices or product availability are not expected from this funding alone.

The takeaway

Interest in human-based testing methods is growing across both government and private investors. Readers following drug development should watch whether these tools gain measurable adoption in pharmaceutical pipelines.

Further reading

For related coverage, explore Healthcare reporting on drug development and medical research trends.

Source note: This article includes information reported by GeekWire.

Live Poll

Should the government spend more to replace animal testing with human-based research methods?